KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Common Equity (2016 - 2025)

Resmed (RMD) has disclosed Common Equity for 16 consecutive years, with $6.3 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 20.33% year-over-year to $6.3 billion, compared with a TTM value of $6.3 billion through Dec 2025, up 20.33%, and an annual FY2025 reading of $6.0 billion, up 22.69% over the prior year.
  • Common Equity was $6.3 billion for Q4 2025 at Resmed, up from $6.1 billion in the prior quarter.
  • Across five years, Common Equity topped out at $6.3 billion in Q4 2025 and bottomed at $2.7 billion in Q1 2021.
  • Average Common Equity over 5 years is $4.3 billion, with a median of $4.2 billion recorded in 2023.
  • The sharpest move saw Common Equity grew 9.8% in 2021, then rose 23.81% in 2023.
  • Year by year, Common Equity stood at $3.1 billion in 2021, then increased by 18.83% to $3.7 billion in 2022, then increased by 19.9% to $4.5 billion in 2023, then increased by 17.21% to $5.3 billion in 2024, then rose by 20.33% to $6.3 billion in 2025.
  • Business Quant data shows Common Equity for RMD at $6.3 billion in Q4 2025, $6.1 billion in Q3 2025, and $6.0 billion in Q2 2025.